Cytotoxicity assays all report killing and they do not report the same thing. One measures membrane rupture, another measures metabolic collapse, a third measures whether the effector cell released its granules at all. Choosing between them on convenience rather than on mechanism is how a program ends up with numbers that disagree and no way to reconcile them.
What each format actually detects
| Readout | Detects | Strength | Limitation |
|---|---|---|---|
| Chromium release | Membrane rupture releasing a loaded label | The long-standing reference method | Radioisotope handling, short labeling window |
| Non-radioactive release assays | Release of an enzyme or dye on lysis | No isotope, plate-based, scalable | Background from spontaneous release |
| Flow-based target loss | Disappearance or dye uptake of labeled targets | Single-cell resolution, can gate on subsets | Lower throughput, more handling |
| Impedance or live-cell imaging | Target adherence or morphology over time | Kinetics rather than one endpoint | Requires adherent targets and dedicated instruments |
| CD107a degranulation | Effector granule release, not target death | Reports effector behavior directly | A proxy; degranulation is not the same as killing |
The last row is the one most often misread. Degranulation tells you the effector engaged and released. Whether the target died is a separate question, and in some conditions the two diverge.
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
Endpoint or kinetics
A single-timepoint readout gives a number. A kinetic readout gives a curve, and the curve frequently contains the finding. Two conditions can reach the same killing at four hours by entirely different routes, one fast and plateauing, the other slow and still climbing. An endpoint assay reports them as equivalent.
Where a mechanism is being compared rather than a magnitude, kinetics is usually worth the additional setup.
The parameters that move results more than the construct
Effector-to-target ratio dominates, and results are not comparable across different ratios. Incubation time interacts with it, since a low ratio given long enough may reach what a high ratio achieves quickly. Target cell line choice changes susceptibility substantially. And whether effectors were rested after thaw changes their functional state, as covered in thawing PBMCs.
Donor variation is signal
Running an assay across several donors produces a spread, and the instinct is to average it. For NK work in particular that spread is informative rather than noisy, because KIR and HLA genotype shape how a given donor’s cells read a given target. The reasoning is in KIR genotyping.
Reporting per donor, with genotype attached where available, converts unexplained variance into a described range. That is a stronger claim than a single averaged figure and it survives review better.
Controls worth building in
Spontaneous release from targets alone sets the floor and drifts with target health. Maximum release defines the ceiling. An effector-only control catches signal from the effector population itself. And where allogeneic effectors and targets are used, a baseline accounting for alloreactivity separate from the antigen-specific effect is worth having.
OrganaBio documents effector populations for this work including peripheral blood NK cells, cord blood NK cells and pan T cells, with donor characterization including KIR and high-resolution HLA typing, and repeat collection for eligible donors so a donor panel stays available across a program.
Frequently asked questions
Which cytotoxicity readout should I use?
It depends on what you need to know. Release assays report membrane rupture, flow-based methods give single-cell resolution, impedance and imaging give kinetics, and CD107a reports effector degranulation rather than target death. Choosing on convenience produces numbers that disagree without a way to reconcile them.
Is degranulation the same as killing?
No. CD107a mobilisation shows the effector engaged and released its granules. Whether the target died is a separate question, and under some conditions the two diverge.
Why choose a kinetic readout over a single endpoint?
Because two conditions can reach the same killing at a fixed timepoint by different routes, one fast and plateauing and one slow and still rising. An endpoint assay reports them as equivalent while a curve distinguishes them.
What affects cytotoxicity results most?
Effector-to-target ratio dominates and results are not comparable across ratios. Incubation time interacts with it, target line choice changes susceptibility substantially, and whether effectors were rested after thaw changes their functional state.
Should I average cytotoxicity results across donors?
For NK work particularly, no. The spread reflects KIR and HLA genotype shaping how each donor reads the target. Reporting per donor with genotype attached converts unexplained variance into a described range.
Which controls does a cytotoxicity assay need?
Spontaneous release from targets alone to set the floor, maximum release to define the ceiling, an effector-only control to catch signal from the effectors themselves, and where allogeneic effectors and targets are used, a baseline for alloreactivity separate from the antigen-specific effect.
What must be reported with a cytotoxicity percentage?
The effector-to-target ratio, incubation time, target cell line and effector source and handling. Without those the number cannot be interpreted or reproduced by anyone else.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
